View the latest information, products, and promotions from Eagle Biosciences in our Eagle i-View Newsletter.
Highlights:
EagleBio Goes Social
Information About Our Latest Webinar- Fertility Research: What is Next?
New Contest & New Prizes
Click here to view the Eagle i-View
Don’t Forget to Subscribe to the EAGLE i-View Newsletter!
The 3rd Quarter Edition is Due Out Soon!
Fascinating Research, Exciting Announcements, Chance to Win Great Prizes!
Visit SUBSCRIBE AT THE BOTTOM OF PAGE
Bats have
always had a bad rap between their nocturnal nature and wealth of myths,
superstition, and gothic literature paints bats in mysterious and in a fearful
light. Contrary to popular myths, bats
seldom transmit disease to other animals or humans. In fact, all mammals can contract rabies but
less than 0.05% of bats that do carry rabies pose
little threat to people WHO DO NOT
HANDLE THEM. In addition, bats are
actually very important to the ecosystem, keeping insects in check and some actually acting as pollinators and seed dispersers. Bat droppings in caves are even useful
in supporting unique organisms, including bacteria useful in detoxifying
wastes, improving detergents and producing gasohol and antibiotics. Read More
So now we
have discussed how bats are important and that we should not fear them, let’s
discuss the situations in which they can be harmful. One of the greatest global health threats and
concerns is emerging diseases, which have never been seen before in humans or as with Ebola which appear sporadically
in new locations. Most emerging diseases
are zoonoses, meaning they are caused by pathogens that can jump from animals
into people. Bats host more than 65
pathogens with one of them being Ebola. Impoverished
nations have been hunting bats as a food source (bushmeat). Remember where we discussed
above that bats are not a typically a threat to those WHO DO NOT HANDLE THEM above? Read More
Image above from the www.theconversation.com.
Nashua, NH:
Eagle Biosciences is now offering unique Antibody Drug Conjugate (ADC) ELISA
Assay Kit menu including MMAE Antibody Drug Conjugate (ADC) ELISA, MMAF
Antibody Drug Conjugate (ADC) ELISA, and DM1 Antibody Drug Conjugate (ADC)
Assay ELISA. These assays will
complement and further expand their current immunology assay portfolio.
The ADC ELISA
Assay kits have excellent sensitivity, wide dynamic range, and can be used with
multiple species and sample types. These
analytes provide incredible value to pre-clinical and clinical pharmacology
studies, cancer research, and more specifically tumor marker investigation. In addition, each of these assays offer
simple procedure with quick results.
“We are
excited to bring the ADC kits to the market.” said Dan Keefe, President of
EagleBio. He continued, “These assays
will help EagleBio reach new emerging market segments in cancer research and
help us to fulfill unmet needs in the field.”
These
products are currently for research use only. Check out the list of Antibody
Drug Conjugate ELISA Assay Kits below. In addition, the antibodies used in
these kits are available for purchase upon special request. Visit the Eagle website, or
call 866-411-8023 for full details.
MMAE Antibody Drug Conjugate (ADC) ELISA Assay Kit
MMAF Antibody Drug Conjugate (ADC) ELISA Assay Kit
DM1 Antibody Drug Conjugate (ADC) ELISA Assay Kit
C. difficile
infections are horribly uncomfortable for patients causing painful
bloating,
cramping, and excessive diarrhea. In
fact, certain strains of C. difficile cause about 250,000
hospitalizations and
14,000 deaths each year in the U.S. The quest for new types of therapy
is because of two big dilemmas with regards to antibiotic treatment.
There is increased antibiotic resistance and they
have a detrimental effect on normal gut flora which protect the body
from
harmful pathogens. So here’s the scoop…there’s now hope with ingesting poop!
Many of you
are probably thinking…ingesting stool that sounds rather disgusting but in fact
it is actually pretty brilliant! This
unique treatment has been the focus of current study at Massachusetts General Hospital
(MGH). A recent press release from the hospital describes this study’s objective to
investigate whether delivering FMT orally through capsules designed to open
upon reaching the small intestine would be just as effective as other more
invasive treatments such as delivering frozen fecal material for FMT either by
colonoscopy or nasogastric tube.
image above from:
A recent abstract pertaining to using LHCGR forms for the prediction of preeclampsia was presented at the 13th World Congress in Fetal Medicine. The World Congress is designed both for those specializing in
fetal-maternal medicine and those with a more general clinical interest
who want to be updated on developments in the field. Leading
international experts and young researchers present and discuss the
latest developments in fetal medicine.
Objective
To explore the possible role of circulating human chorionic gonadotrophin receptor (LHCGR) forms in the prediction of early and late preeclampsia (PE) in the first trimester of pregnancy, combined with maternal baseline risk, biophysical parameters and angiogenic factors.
Methods
A case-control study, within a cohort of 5, 759 pregnancies including 20 cases of early PE, 20 of late PE (cut-off: 34 weeks at delivery), 300controls. Maternal characteristics, mean arterial pressure (MAP), uterine artery (UtA) Doppler (11-13 weeks), placental growth factor (PlGF),soluble Fms-like tyrosine kinase-1 (sFtl-1), circulating sLHCGR, and hCG-LHCGR complexes (8-11 weeks) were measured/recorded. LHCGR difference (LHCGR-D) was calculated by subtracting hCG-LHCGR value from the corresponding sLHCGR. All parameters were normalized by logarithmic transformation, converted in MoM, and logistic regression analysis was used to predict PE.
Conclusion
Among LHCGR forms, the LHCGR-D improves substantially the prediction for early and late PE in first trimester, if used in algorithms. These new biomarkers seemed useful if used in combination (LHCGR-D) in the context of prediction of PE.
READ Entire AACC Scientific Abstract HERE
Eagle Biosciences recently announced a North American distribution agreement with Matriks Biotek. Matriks develops and manufactures unique ELISA test kits and monoclonal antibodies with a strong focus on meeting research needs and creating products to better understand a variety of diseases and conditions in areas such as inflammation, immunology, gastrology, oncology, diabetes and obesity, and reproductive science.
“Matriks Biotek products bring a multitude of esoteric products to EagleBio.” said Dan Keefe President of EagleBio. He continued, “This is a great collaboration with respect to EagleBio’s goals to continually seek out quality, unique scientific tools and Matriks Biotek’s quest for R&D innovations and special interest for biotherapeutics and novel markers for diseases.” Keefe continued, “We are especially excited about Matriks’ Shikari® ELISA kits and anti-drug antibody ELISA assay kit product line.” He continued, “These can be efficiently used, for monitoring serum trough levels and the presence of anti-drug antibodies respectively.”
These products are currently for research use only. Check out the list of Matrik Biotek products below. Visit the Eagle website www.EagleBio.com or call 866-411-8023 for full details.
Infliximab (Remicade®) Antibodies ELISA Assay kit
Free Adalimumab (Humira®) ELISA Assay Kit
Adalimumab (Humira®) Antibodies ELISA Assay Kit
Etanercept (Enbrel®) ELISA Assay Kit
Etanercept (Enbrel®) Antibodies ELISA Assay Kit
Bevacizumab (Avastin®) ELISA Assay Kit
Bevacizumab (Avastin®) Antibodies ELISA Assay Kit
Trastuzumab (Herceptin®, Herclon®).ELISA Assay Kit
Trastuzumab (Herceptin®, Herclon®) Antibodies ELISA Assay Kit
image from www.pinkribbonblues.org
In honor of breast cancer awareness month, we thought we would
share some interesting and hopeful new research. But before discussing
this we should take some time to reflect on the fact that people
afflicted by this disease are battling it everyday and some for
several years. It does seem trivial to only recognize it one month of
every year when you consider all of this, but perhaps this is our way of
setting time aside to focus attention and in some way bring energy,
good vibes, and perhaps fresh ideas to conquer this disease.
A recent study done by the University of Michigan focused on
selecting novel monoclonal antibodies with anticancer activity. They
did this by creating an environment of cancer cells in vitro and then
exposing these cells to numerous antibodies to evaluate if these
antibodies have any anti-cancer fighting effects. How they created the
antibodies is rather intriguing. Read more.
Type 1 diabetes, also known as insulin-dependent diabetes mellitus, results from a chronic autoimmune process which destructs the insulin-secreting pancreatic beta cells. Before the onset of disease T1D patients may demonstrate autoantibodies against different autoantigens of islet cells. Research indicates that these autoantibodies have been shown to be important markers for the identification of individuals with an increased risk to develop T1D at a time when all metabolic tests available still show normal results.
Islet cell autoantibodies detected by indirect immunofluorescence (IIF) have been the first serological markers described for T1D. This technique using tissue sections from human or primate pancreas, however, still reveals methodological problems, especially with regard to inter-laboratory standardization. After discovery of the two main protein antigens of ICA – the enzyme glutamic acid decarboxylase (GAD65) and the islet cell protein IA2 – it has been possible to measure these specific autoantibodies by radioligand assays and recently by sensitive ELISA.
Risk assessment of T1D can be achieved by the combination of tests for these different autoantibodies. Therefore, the Eagle Biosciences ICA screen ELISA Assay kit – designed for the semiquantitative determination of ICA to enable reliable screening – was compared with IIF as the routine method for the detection of ICA.
Conclusion:
The Eagle Biosciences ICA screen ELISA Assay Kit is a robust and sensitive tool for the detection of ICA. In comparison with established methods for the detection of ICA, this assay showed superior sensitivity. These data strongly support further investigation to confirm the better sensitivity of the ICA screen ELISA.
The
very thought of being able to grow actual human organs in a laboratory is mind
blowing! There are endless possibilities
for medical research with a recent study performed at the MRC Centre of
Regenerative Medicine in Edinburgh, U.K. Scientists were successfully able to cultivate living cells from an
animal in vitro. The process that they used to do this could
be used for a multitude of medical purposes and therapies for transplant
patients and more. This study was
focused on creating a functional thymus for mice but it brings hope that this process could be
used for humans for creating a variety of other organ tissues. Read more.
